US04301G5080 - Common Stock
Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artelo Biosciences (NASDAQ:ARTL) just reported results for the fourth quarter o...
Major achievements in 2023 lay the foundation for key upcoming milestones...
ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson...
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states...
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to Submit IND...
SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
We're diving into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024...
New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in...
SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the Award...
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic...
ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ...